FDA panel unanimously votes down Parkinson's drug

October 17, 2011

A panel of federal medical specialists has unanimously voted that a drug for Parkinson's disease from Teva Pharmaceuticals has not been shown to slow progress of the debilitating neurological disease.

Teva's Azilect is already approved to treat symptoms of Parkinson's, which causes tremors, and loss of balance.

Teva has asked the to expand approval so that it can be prescribed to slow the underlying disease. Currently no treatments are approved for that use.

But the FDA's panel of outside experts voted 17-0 against recommending approval for that use, saying the company's clinical study results were not convincing.

shares

Related Stories

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.